Drug Profile
Epoetin alfa biosimilar - Reliance Life Sciences
Alternative Names: Epostim; ReliPoietinLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator GeneMedix Plc
- Developer Reliance GeneMedix; Reliance Life Sciences; Stragen Pharma SA
- Class Antianaemics; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists; Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Anaemia
Most Recent Events
- 19 May 2015 No recent reports of development identified - Preregistration for Anaemia in European Union (Parenteral)
- 15 Mar 2011 Reliance Life Sciences withdraws its Marketing Authorisation Application with the European Medicines Agency
- 29 Oct 2010 Preregistration for Anaemia (chemotherapy induced) in European Union (Parenteral)